148 related articles for article (PubMed ID: 33527905)
1. Mast cells (MC) excess in a bone marrow (BM) associated with lymphoplasmacytic cells (LPC) in a 55-Y-old patient with Waldenström's macroglobulinemia (WM).
Gentelet M; Demulder A
Ann Biol Clin (Paris); 2021 Feb; 79(1):92-93. PubMed ID: 33527905
[No Abstract] [Full Text] [Related]
2. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling.
Tournilhac O; Santos DD; Xu L; Kutok J; Tai YT; Le Gouill S; Catley L; Hunter Z; Branagan AR; Boyce JA; Munshi N; Anderson KC; Treon SP
Ann Oncol; 2006 Aug; 17(8):1275-82. PubMed ID: 16788002
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
Jalali S; Ansell SM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
Ahn A; Park CJ; Cho YU; Jang S; Seo EJ; Lee JH; Yoon DH; Suh C
Ann Lab Med; 2020 May; 40(3):193-200. PubMed ID: 31858758
[TBL] [Abstract][Full Text] [Related]
5. Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia.
Dogliotti I; Jiménez C; Varettoni M; Talaulikar D; Bagratuni T; Ferrante M; Pérez J; Drandi D; Puig N; Gilestro M; García-Álvarez M; Owen R; Jurczak W; Tedeschi A; Leblond V; Kastritis E; Kersten MJ; D'Sa S; Kaščák M; Willenbacher W; Roccaro AM; Poulain S; Morel P; Kyriakou C; Fend F; Vos JMI; Dimopoulos MA; Buske C; Ferrero S; García-Sanz R
Leukemia; 2023 Feb; 37(2):388-395. PubMed ID: 36435884
[TBL] [Abstract][Full Text] [Related]
6. Lymphoplasmacytic lymphoma with IgA paraproteinemia mimicking Waldenstrom's Macroglobulinemia.
Basu D; Pathak D; Shyambabu C; Koner BC; Swaminathan RP
Indian J Pathol Microbiol; 2004 Oct; 47(4):515-7. PubMed ID: 16295380
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
8. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
[TBL] [Abstract][Full Text] [Related]
9. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of Waldenström macroglobulinemia.
McMaster ML
Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
[TBL] [Abstract][Full Text] [Related]
11. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM).
Kobayashi Y
Int J Hematol; 2019 Nov; 110(5):524-528. PubMed ID: 31494831
[No Abstract] [Full Text] [Related]
12. Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.
Kyle RA; Ansell SM; Kapoor P
Best Pract Res Clin Haematol; 2016 Jun; 29(2):179-186. PubMed ID: 27825464
[TBL] [Abstract][Full Text] [Related]
13. Mast cell density and its clinical relevance in Waldenström's macroglobulinemia.
Lemal R; Poulain S; Ledoux-Pilon A; Veronese L; Tchirkov A; Lebecque B; Tassin T; Bay JO; Charlotte F; Nguyen-Khac F; Berger M; Godfraind C; Ysebaert L; Davi F; Pereira B; Leblond V; Hermine O; Guièze R; Pagès F; Tournilhac O
EJHaem; 2022 May; 3(2):371-378. PubMed ID: 35846063
[TBL] [Abstract][Full Text] [Related]
14. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
15. Immunochemical studies in a patient with Waldenstrom's macroglobulinemia.
Mir-Ahmadian M; Rahbar S; Heidery H; Hajaliloo G
Acta Med Iran; 1978; 21(1):39-46. PubMed ID: 110036
[TBL] [Abstract][Full Text] [Related]
16. Report of the Third International Workshop on Waldenstrom's macroglobulinemia.
Treon SP; Morel P; Leblond V; Fermand JP
Clin Lymphoma; 2005 Mar; 5(4):215-6. PubMed ID: 15794850
[No Abstract] [Full Text] [Related]
17. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
[TBL] [Abstract][Full Text] [Related]
18. Waldenstrom's macroglobulinemia in the era of immunotherapy.
Vaxman I; Gertz M
Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
[TBL] [Abstract][Full Text] [Related]
19. Assessment of bone marrow response in Waldenström's macroglobulinemia.
Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
[TBL] [Abstract][Full Text] [Related]
20. Developing diagnostic criteria in Waldenstrom's macroglobulinemia.
Owen RG
Semin Oncol; 2003 Apr; 30(2):196-200. PubMed ID: 12720135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]